A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Patients With Chronic Hepatitis B.

This study has been withdrawn prior to enrollment.

(This study was canceled for operational reasons.)

Sponsor:

Information provided by (Responsible Party):

Hoffmann-La Roche

ClinicalTrials.gov Identifier:

NCT01179594

First received: August 10, 2010

Last updated: June 3, 2013

Last verified: June 2013

No Study Results Posted on ClinicalTrials.gov for this Study

Study was withdrawn before participants were enrolled.

Study Status:	This study has been withdrawn prior to enrollment.
Estimated Study Completion Date:	November 2014
Estimated Primary Completion Date:	No date given